This remarkable improvement in survival underscores the importance of testing metastatic LCNEC for biomarkers, such as <i>ALK</i> rearrangement, using immunohistochemistry or next-generation sequencing, especially in younger patients. This evidence concerns the gene ALK and large cell neuroendocrine carcinoma.